Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Baloxavir treatment of ferrets infected with influenza A(H1N1)pdm09 virus reduces onward transmission.
Lee LYY, Zhou J, Frise R, Goldhill DH, Koszalka P, Mifsud EJ, Baba K, Noda T, Ando Y, Sato K, Yuki AI, Shishido T, Uehara T, Wildum S, Zwanziger E, Collinson N, Kuhlbusch K, Clinch B, Hurt AC, Barclay WS. Lee LYY, et al. Among authors: zwanziger e. PLoS Pathog. 2020 Apr 15;16(4):e1008395. doi: 10.1371/journal.ppat.1008395. eCollection 2020 Apr. PLoS Pathog. 2020. PMID: 32294137 Free PMC article.
Pharmacologic effects of oseltamivir in immunocompromised adult patients as assessed by population PK/PD analysis and drug-disease modelling for dosing regimen optimization.
Sturm S, Lemenuel-Diot A, Patel K, Gibiansky L, Bhardwaj R, Smith PF, Dang S, Zwanziger E, Nasmyth-Miller C, Ravva P. Sturm S, et al. Among authors: zwanziger e. Br J Clin Pharmacol. 2021 Mar;87(3):1359-1368. doi: 10.1111/bcp.14523. Epub 2020 Sep 9. Br J Clin Pharmacol. 2021. PMID: 32808306 Free PMC article.
Dosing regimen optimisation for oseltamivir in immunocompromised paediatric patients with influenza: Extrapolation of efficacy.
Jordie EB, Gibiansky L, Knab T, Lemenuel-Diot A, Ravva P, Zwanziger E, Jolivet S, Bhardwaj R, Hernández-Sánchez J, Nasmyth-Miller C, Sturm S. Jordie EB, et al. Among authors: zwanziger e. Br J Clin Pharmacol. 2022 Mar;88(3):1189-1201. doi: 10.1111/bcp.15059. Epub 2021 Oct 15. Br J Clin Pharmacol. 2022. PMID: 34449090 Free article.
Drug-drug interaction study of ketoconazole and ritonavir-boosted saquinavir.
Kaeser B, Zandt H, Bour F, Zwanziger E, Schmitt C, Zhang X. Kaeser B, et al. Among authors: zwanziger e. Antimicrob Agents Chemother. 2009 Feb;53(2):609-14. doi: 10.1128/AAC.00769-08. Epub 2008 Nov 17. Antimicrob Agents Chemother. 2009. PMID: 19015329 Free PMC article. Clinical Trial.
Safety and Pharmacokinetic Characterization of Nacubactam, a Novel β-Lactamase Inhibitor, Alone and in Combination with Meropenem, in Healthy Volunteers.
Mallalieu NL, Winter E, Fettner S, Patel K, Zwanziger E, Attley G, Rodriguez I, Kano A, Salama SM, Bentley D, Geretti AM. Mallalieu NL, et al. Among authors: zwanziger e. Antimicrob Agents Chemother. 2020 Apr 21;64(5):e02229-19. doi: 10.1128/AAC.02229-19. Print 2020 Apr 21. Antimicrob Agents Chemother. 2020. PMID: 32041717 Free PMC article.
In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK).
Meneses-Lorente G, Fowler S, Guerini E, Kowalski K, Chow-Maneval E, Yu L, Mercier F, Ullah M, Umehara K, Brink A, Buchheit V, Zwanziger E, Phipps A, Djebli N. Meneses-Lorente G, et al. Among authors: zwanziger e. Invest New Drugs. 2022 Feb;40(1):68-80. doi: 10.1007/s10637-021-01156-9. Epub 2021 Aug 21. Invest New Drugs. 2022. PMID: 34417912 Free PMC article.
15 results